These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 5443539)

  • 41. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
    Waller EK; Barlett N; Chen CH; Mujic V; Sussman H; Toepker S; Grenier K
    Cytotherapy; 1999; 1(1):21-9. PubMed ID: 19746646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
    Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination chemoimmunotherapy for advanced renal carcinoma with Adriamycin, bleomycin, vincristine, cyclophosphamide, plus BCG.
    Dana BW; Alberts DS
    Cancer Clin Trials; 1981; 4(2):205-7. PubMed ID: 6166407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
    Inoue K; Ogawa M; Inagaki J; Horikoshi N; Ikeda K; Nakada H; Usui N; Adachi K; Tada A; Yamazaki H
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1832-7. PubMed ID: 6433805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.
    ten Berge RJ; van Walbeek HK; Schellekens PT
    Clin Exp Immunol; 1982 Dec; 50(3):495-502. PubMed ID: 7165996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drug induced pulmonary disease. Diffuse interstitial pneumonitis during chemoradiotherapy for small cell carcinoma of the lung. Two cases (author's transl)].
    Riou R; Duvillard P; Touraine R
    Poumon Coeur; 1982; 38(1):57-62. PubMed ID: 6283505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Continuing therapy of advanced liver tumors using cyclophosophamide].
    Nerad V; Dvorácková I; Hůlek P; Dítĕ P; Fendrichová M
    Cesk Gastroenterol Vyz; 1978 Dec; 32(8):534-5. PubMed ID: 104794
    [No Abstract]   [Full Text] [Related]  

  • 50. [Results of a cooperative therapy study with cyclophosphamide and roentgen rays of malignant tumors in childhood].
    Neidhardt M
    Monatsschr Kinderheilkd (1902); 1970 Jun; 118(6):304-5. PubMed ID: 5523667
    [No Abstract]   [Full Text] [Related]  

  • 51. Dimethyl sulfoxide therapy as toxicity-reducing agent and potentiator of cyclophosphamide in the treatment of different types of cancer.
    Garrido JC; Lagos RE
    Ann N Y Acad Sci; 1975 Jan; 243():412-20. PubMed ID: 236715
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclophosphamide and malignancy.
    Puri HC; Campbell RA
    Lancet; 1977 Jun; 1(8025):1306. PubMed ID: 68399
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical experiences in the use of cyclphosphamide (Endoxan)].
    Aksoycan S; Tauschwitz K
    Med Welt; 1965 Jun; 26():1450-4. PubMed ID: 5318700
    [No Abstract]   [Full Text] [Related]  

  • 54. [Longterm intra-arterial infusion in the treatment of malignant tumors].
    Vojtísek V; Lorenc J; Topol O; Abrahamovic M; Jelínek V
    Rozhl Chir; 1966 Feb; 45(2):140-6. PubMed ID: 5913623
    [No Abstract]   [Full Text] [Related]  

  • 55. [A case of malignant mouth neoplasm treated conservatively].
    Betkowski A
    Wiad Lek; 1970 Mar; 23(5):411-3. PubMed ID: 5437077
    [No Abstract]   [Full Text] [Related]  

  • 56. [Experimental studies on the multistep cancer therapy concept in healthy pigs].
    Braun W; Buchholz W; Barth J; Hartmann H; Kipping D; Ludewig R; Nitzschner H; Schmoranzer H; Standau H; Zintzsch I
    Arch Geschwulstforsch; 1972; 39(3):220-8. PubMed ID: 5053753
    [No Abstract]   [Full Text] [Related]  

  • 57. Alopecia activity of cyclophosphamide metabolites and related compounds in sheep.
    Feil VJ; Lamoureux CH
    Cancer Res; 1974 Oct; 34(10):2596-8. PubMed ID: 4411919
    [No Abstract]   [Full Text] [Related]  

  • 58. Cyclophosphamide: a drug profile.
    Chan MK
    J Assoc Pediatr Oncol Nurses; 1984; 1(3):30-3. PubMed ID: 6565777
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cyclophosphamide--current clinical studies in Great Britain].
    Simister JM
    Laval Med; 1968 Oct; 39(8):748-54. PubMed ID: 5748240
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclophosphamide in chronic active hepatitis.
    Althouse R; Huff JE; Tomatis L; Wilbourn JD
    Br Med J; 1979 Jun; 1(6178):1630-1. PubMed ID: 466166
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.